ALL >> General >> View Article
Ascentage Pharma & Astrazeneca Partner For Cll Study
Ascentage Pharma, a global biopharmaceutical company focused on developing innovative treatments for cancer, chronic hepatitis B (CHB), and age-related diseases, has announced a significant clinical collaboration with AstraZeneca Investment (China) Co., Ltd. This collaboration is centered around conducting a Phase III study of APG-2575 (lisaftoclax), a Bcl-2 inhibitor developed by Ascentage Pharma, in combination with AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor, CALQUENCE® (acalabrutinib). The study will focus on treatment-naive patients with first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This global, multi-center, randomized-controlled, Phase III trial aims to evaluate the effectiveness and safety of lisaftoclax combined with acalabrutinib compared to immunochemotherapy in treatment-naïve CLL/SLL patients.
This collaboration builds on a previous Phase II study conducted in partnership with Acerta Pharma, a subsidiary of AstraZeneca. In that study, the lisaftoclax and acalabrutinib combination demonstrated strong therapeutic potential, with impressive response rates in ...
... patients with CLL/SLL and a favorable safety profile.
CLL/SLL is a common hematologic malignancy affecting adults, particularly in the Western world. In China, it's increasingly prevalent and more aggressive, presenting a significant health threat. Despite advancements in targeted therapies, there's a pressing need for treatments that offer both efficacy and safety.
Lisaftoclax is a novel Bcl-2 selective inhibitor developed by Ascentage Pharma. It's designed to block the antiapoptotic protein Bcl-2, thereby restoring the normal apoptosis process in cancer cells. Acalabrutinib, on the other hand, is a highly selective BTK inhibitor. This partnership represents an essential step toward offering patients in China more effective and safer treatments for hematologic malignancies.
This collaboration signifies a commitment to addressing unmet clinical needs in the field of cancer treatment. Results from ongoing clinical studies suggest that the combination of lisaftoclax and acalabrutinib holds significant therapeutic potential. Both companies are dedicated to advancing this clinical development program to benefit a broader population of patients and bring innovative therapies to the forefront.
In a rapidly evolving field like oncology, partnerships between biopharmaceutical companies are essential for advancing treatments and improving patient outcomes. This collaboration reflects a commitment to innovation and improving the lives of those affected by hematologic malignancies.
More Information : https://www.techdogs.com/tech-news/pr-newswire/ascentage-pharma-and-astrazeneca-enter-into-clinical-collaboration-on-the-registrational-phase-iii-study-of-bcl-2-inhibitor-lisaftoclax-in-combination-with-btk-inhibitor-acalabrutinib-in-treatment-nave-patients-with-first-line-cll-sll
Add Comment
General Articles
1. Blockchain And Ai: Innovative Ways They Can Work Together ShapeAuthor: QSS Technosoft
2. Join The Vidyavision Student Community
Author: vidyavision
3. Hair Growth 101: Scandinavian Biolabs’ Guide To Healthier, Fuller Hair
Author: Jonson Jon
4. The Ultimate Guide To Ordering Flowers In Barcelona
Author: order flowers Barcelona
5. Máy Hút ẩm Công Nghiệp Kosmen
Author: BPS Việt Nam
6. How Beneficial The Cleaning Products Can Be?
Author: Edward Smith
7. The Role Of Glass Cloth Electrical Tape In Power Transformers
Author: jarod
8. Combatting Carotid Artery Stenosis: Effective Strategies For Prevention And Care
Author: Dr. Sumit Kapadia
9. How Managed It Services Are Shaping The Future Of Support
Author: ICSI
10. Leading System Aluminium Doors & Windows Manufacturer In Amritsar
Author: Sleek Edge
11. Exploring The Opportunities At Anantrao Pawar College Of Engineering
Author: AnantraoPawarCollege
12. Home Remodeling Contractors Around South Lyon
Author: manish
13. Blockdag Crypto Mining Rigs
Author: BlockDAG
14. Discover The Power Of Branding Courses: Boost Your Skills And Advance Your Career
Author: Andrew F.
15. Panorama Test: A Complete Guide To Non-invasive Prenatal Screening
Author: Stan Jan